

Low serum 25(OH)D₃ in patients newly diagnosed with T2DM

June 15 2015



(HealthDay)—Serum 25-hydroxyvitamin D₃ (25[OH]D₃) is associated with glucose-stimulated insulin secretion and β -cell function in individuals with newly diagnosed type 2 diabetes, according to a study published online June 5 in the *Journal of Diabetes Investigation*.

Yan Yang, from the Sichuan Provincial People's Hospital in Chengdu, China, and colleagues recruited 97 newly diagnosed type 2 diabetes patients and 69 healthy controls to assess 25(OH)D₃. The authors determined 25(OH)D₃ using high pressure liquid chromatography. The correlations of 25(OH)D₃ with insulin resistance and β -[cell function](#) were assessed.

The researchers found that patients with newly diagnosed [type 2 diabetes](#)

had much lower serum 25(OH)D₃ (P₃ in patients with diabetes was 62.9 percent. Among patients with diabetes, those with hypovitaminosis 25(OH)D₃ had higher hemoglobin A1c (HbA1c) and area under the curve for glucose (P insulin secretion index, and area under the insulin curve. There was an independent positive correlation for serum 25(OH)D₃ with early-phase insulin secretion index and area under the insulin curve (P₃.

"Serum 25(OH)D₃ is not correlated with basal [insulin resistance](#) or β -cell function but is significantly positively correlated with glucose-stimulated insulin secretion and β -cell function," the authors write.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Low serum 25(OH)D₃ in patients newly diagnosed with T2DM (2015, June 15)
retrieved 26 April 2024 from
<https://medicalxpress.com/news/2015-06-serum-25ohd3-patients-newly-t2dm.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--